---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-184488"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2022-06-29T23:59:59+00:00"
generated_at: "2026-06-24T22:19:43.051909+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Aileron stops NSCLC trial enrollment after interim data; revises breast cancer trial

## Summary
- Interim data from 20 patients: ALRN-6924 patients completed 93% of first 4 chemo cycles vs 78% placebo.
- Progression-free survival median 4.6 months on ALRN-6924 vs 3.2 months on placebo.
- Composite primary endpoint: 56% cycles free of Grade ≥3 hematologic toxicities vs 50% placebo.
- Plans to stop further NSCLC enrollment; apply learnings to breast cancer trial with revised dosing and endpoint.
- Will not further enroll 0.3 mg/kg and 0.6 mg/kg cohorts in breast cancer trial; higher dose to be evaluated.

## SEC filing metadata
- accession: 0001193125-22-184488
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2022-06-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312522184488/0001193125-22-184488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312522184488/d314855d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-184488
- JSON: https://secwatch.observer/filing/0001193125-22-184488.json
- Plain text: https://secwatch.observer/filing/0001193125-22-184488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.